Neology, Inc.

Genentech, Inc.

Novartis Ag

Coherus Biosciences, Inc.

Technocom Corporation

Smartrac Technology Fletcher, Inc.

Kapsch Trafficcom Ag

Genetech, Inc.

Jun Liu

Steven J Shire

Jeffrey Zhu

Mark Cornell Manning

Thomas Tahan

Justin Paul McNew

Francisco Martinez De Velasco Cortina

John Azevedo

John B Fairbanks

Sheshidher Nyalamadugu

Douglas Moran

Khaled I Dessouky

Isaias Prado

Rodolfo Monsalvo

Eric Ian Mikuteit

James Andya

Johnny Yat Ming Chan

Ye Shen

Junyan Ji

Shiang C Gwee

John Ogez

Yuchang John Wang

Wenchang Ji

Patrick Daniel Begley

Joe Mullis

Qing Zhu

Dirk Behnke

Juergen Klaus Maibaum

Timothy Z Hoffman

Feng Cong

Sekhar Kanapuram

Jennifer Harris

Qihui Jin

Xiaomo Jiang

Yefen Zou

Jianwei Che

Yun Feng Xie

Arick Michael Brown

Jianfeng Pan

Chih-chuan Yen

Xueshi Hao

Huaixiang Hao

Cameron Lee

Jie Li

Arnaud Lacoste

Robert Charles Blakely

Bruce Kabakoff

Barthelemy Luc Demeule

Tingting Mo

Nicole Piros

Hsin-I Hsieh

Nicholas Ng

Frada Berenshteyn

Yahu Liu

Xin Qu

Jan Tchorz

Shanshan Yan

Ankit R Patel

Timothy Hoffman

James D Andya

A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of aflibercept, wherein the formulation is free of organic co-solvent and/or free of buffer; methods for making such a formulation; and methods of using such a formulation.

Stable aqueous formulations of aflibercept

The disclosure provides stable pharmaceutical compositions comprising an anti-CD79b immunoconjugate and a surfactant. The disclosure also provides methods for using such compositions for the treatment of cancer.

Stable anti-CD79B immunoconjugate formulations

The present invention is directed to compositions and methods for stabilizing a protein without a surfactant. The present invention is further directed to compositions comprising a protein and at least one excipient selected from the group consisting of hindered amines, anionic aromatics, functionalized amino acids, oligopeptides, low molecular weight aliphatic polyacids, zwitterions, phospholipids, cyclodextrins, polyethylene glycols, gelatins, urea, ethanol, glycerin, dextran, xanthan gum, 2-(2-ethoxyethoxy)ethanol, hydroxypropyl cellulose, propylene glycol, a short-chain organic acid, deoxycholate, sodium nitrate, sodium sulfate, proline and lysine.

Stable protein compositions and methods of their use

The present invention is directed to methods for filling a container wherein the filled container has no headspace. The present invention is further directed to methods for stabilizing an aqueous drug substance solution by filling a container with the aqueous drug substance solution wherein the filled container has no headspace. The present invention is further directed to methods for detecting headspace in a container.

Method of filling a container with no headspace

The present invention is related to 6-6 Fused Bicyclic Heteroaryl Compounds of the Formula A2 or A1 and their Use as LATS Inhibitors, or a salt, stereoisomer or pharmaceutical composition thereof; wherein the variables are as defined herein. The present invention further relates to a method of LATS inhibition in a cell population using a compound of Formula A1, or a salt, stereoisomer or pharmaceutical composition thereof. The present invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, their use in the treatment and management of diseases or disorders.

6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors

The invention provides methods of reducing fouling of ultrafiltration membranes in processes wherein virus particles are removed from aqueous solutions comprising virus particles and at least one protein by adding a surfactant or non-surfactant, non-ionic agent to the aqueous solution prior to filtration. The invention also provides methods to dissociate protein aggregates or to reduce the formation of protein aggregates by adding a surfactant or non-surfactant, non-ionic agent to the protein solution.

Protein purification methods

The invention provides methods of monitoring differential gene expression of biomarkers to determine patient sensitivity to Wnt inhibitor, methods of determining the sensitivity of a cell to an Wnt inhibitor by measuring biomarkers, methods of screening for candidate Wnt inhibitor, Wnt inhibitor for use in head and neck squamous cell carcinoma.

Markers associated with Wnt inhibitors

A method for mutual authentication in an RFID system comprising an RFID reader and an RFID tag, the method comprising requesting an identification from the tag, receiving the identification, using the received identification to select a password associated with the identification, generating a password key based on the selected password, encrypting the selected password using the password key, and transmitting the encrypted password to the tag.

RFID authentication architecture and methods for RFID authentication

A method for authenticating a document comprises obtaining the contents of a document, obtaining biometric characteristics from an individual, forming a message based on the contents of the document and the biometric characteristics of the individual, generating a digital signature based on the message and a key, and writing the digital signature to an Radio Frequency Identification (RFID) tag affixed to the document.

Systems and methods for authenticating and providing anti-counterfeiting features for important documents

The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method for reducing the viscosity of concentrated protein formulations.

Reduced-viscosity concentrated protein formulations

A method for updating a group encryption key association, the method includes receiving an encrypted group key from a second device, where the group key has been encrypted using a device key of a first device. The method further includes, in the first device, using the group key to encrypt an input vector, transmitting the encrypted input vector, encrypting privacy-sensitive information using a device key, an encryption algorithm, and the input vector, and transmitting the encrypted privacy-sensitive information to the second device.

Systems and methods for preventing transmitted cryptographic parameters from compromising privacy

The present application relates to highly concentrated antibody and protein formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration. The application further describes articles of manufacture containing such formulations and method for using them to treat disorders treatable by the formulated antibody or protein.

High concentration antibody and protein formulations

Growing community of inventors

San Diego, CA, United States of America

Jun Liu